Subscribe
marianvejcik-istockphoto-com-gavel-uk-
27 October 2017Big Pharma

Teva suffers defeat as Copaxone claims invalidated

The English High Court has invalidated two patent claims protecting Copaxone (glatiramer acetate), a billion-dollar drug marketed by Teva.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Teva drops Copaxone generic suit against Mylan
12 December 2017   Teva has dropped its litigation over two US patents against Mylan, after a district court adopted Mylan’s interpretation of the patents.
Americas
Teva to appeal against invalidation of Copaxone patents
31 January 2017   Teva will appeal against a decision which saw the invalidation of four patents covering its multiple sclerosis drug Copaxone.
Big Pharma
Teva survives Copaxone patent challenge
22 May 2015   Teva has successfully defended two patents related to its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate) at the English High Court.


Editor's picks

Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025

Editor's picks

Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Europe
Four firms reach highest tier in WIPR’s 2025 Global Trade Secrets Rankings
18 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025

More on this story

Big Pharma
Teva drops Copaxone generic suit against Mylan
12 December 2017   Teva has dropped its litigation over two US patents against Mylan, after a district court adopted Mylan’s interpretation of the patents.
Americas
Teva to appeal against invalidation of Copaxone patents
31 January 2017   Teva will appeal against a decision which saw the invalidation of four patents covering its multiple sclerosis drug Copaxone.
Big Pharma
Teva survives Copaxone patent challenge
22 May 2015   Teva has successfully defended two patents related to its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate) at the English High Court.

More on this story

Big Pharma
Teva drops Copaxone generic suit against Mylan
12 December 2017   Teva has dropped its litigation over two US patents against Mylan, after a district court adopted Mylan’s interpretation of the patents.
Americas
Teva to appeal against invalidation of Copaxone patents
31 January 2017   Teva will appeal against a decision which saw the invalidation of four patents covering its multiple sclerosis drug Copaxone.
Big Pharma
Teva survives Copaxone patent challenge
22 May 2015   Teva has successfully defended two patents related to its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate) at the English High Court.

More features

Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
UK firm expands in Germany with more litigation hires
Sandoz blocked by UK court from seeking Xarelto profits
An update on patenting in Ukraine, Russia and Eurasia
The rise of pro-NPE and patent sentiment in the US
UPC sees rising small molecule litigation with Pfizer in the hot seat
Why the Caribbean cannabis economy is ripe for IP protection
China filings push rise in patent applications in Ireland